NVALT-studies Stichting

The research portfolio is centered on completely resected primary stage IB, stage II, and stage IIIA non-small cell lung cancer, with interest in patients whose tumors show PD-L1 expression and lack EGFR and ALK alterations.

• Adjuvant treatment after complete resection
• PD-L1–selected lung cancer populations
• Early-stage and locally advanced disease

Work in this area reflects a focus on postoperative disease control and outcomes in surgically treated lung cancer.